Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/13524585211003476 http://scihub22266oqcxt.onion/10.1177/13524585211003476 33856242!8114441!33856242     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mult+Scler 2021 ; 27 (6): 864-870 Nephropedia Template TP {{tp|p=33856242|t=2021. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 |pdf=|usr=}}{{33856242}} gab.com Text COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 JO: Mult Scler http://www.kidney.de/pget.php?&tw=1&pmid=33856242 #FOAvip BACKGROUND: Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed. OBJECTIVE: Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients. METHODS: We assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients. RESULTS: Between 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18-55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ?3.0), and in patients treated with immunomodulatory drugs. CONCLUSION: COVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted. Twit Text FOAVip COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 ????Mult Scler http://www.kidney.de/pget.php?&tw=1&pmid=33856242 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33856242 #FOAvip English Wikipedia <ref>{{Cite pmid|33856242}}</ref> COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 #MMPMID33856242 Achiron A; Dolev M; Menascu S; Zohar DN; Dreyer-Alster S; Miron S; Shirbint E; Magalashvili D; Flechter S; Givon U; Guber D; Stern Y; Polliack M; Falb R; Gurevich M Mult Scler 2021[May]; 27 (6): 864-870 PMID33856242show ga BACKGROUND: Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed. OBJECTIVE: Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients. METHODS: We assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients. RESULTS: Between 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18-55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ?3.0), and in patients treated with immunomodulatory drugs. CONCLUSION: COVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted. |*Vaccination[MESH] |Adolescent[MESH] |Adult[MESH] |Age Factors[MESH] |Aged[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/*adverse effects/*therapeutic use[MESH] |COVID-19/complications/epidemiology[MESH] |Cohort Studies[MESH] |Disability Evaluation[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Sclerosis/*complications[MESH] |Patient Safety[MESH] |Recurrence[MESH]COVID-19 vaccination in patients with multiple sclerosis: What we have(epmc).pdf DeepDyve Pubget Overpricing